Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$24.40 USD

24.40
2,150,803

+0.60 (2.52%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $24.39 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why

by Zacks Equity Research

Atara's (ATRA) shares fell after a phase II study evaluating its multiple sclerosis therapy did not meet its primary endpoint.

Zacks Equity Research

Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.

Zacks Equity Research

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

by Zacks Equity Research

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.

Zacks Equity Research

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

by Zacks Equity Research

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

Zacks Equity Research

Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance

by Zacks Equity Research

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.

Ekta Bagri headshot

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

Zacks Equity Research

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

by Zacks Equity Research

Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.

Zacks Equity Research

J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant

by Zacks Equity Research

J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).

Zacks Equity Research

Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment

by Zacks Equity Research

Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.

Zacks Equity Research

Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug

by Zacks Equity Research

Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.

Zacks Equity Research

Wall Street Analysts Predict a 37.65% Upside in Acadia (ACAD): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Acadia (ACAD) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

by Zacks Equity Research

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Zacks Equity Research

Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug

by Zacks Equity Research

Data from an early-stage study shows that treatment with Karuna's (KRTX) KarXT was not associated with clinically meaningful increases in blood pressure in schizophrenia patients.

Zacks Equity Research

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

by Zacks Equity Research

Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.

Zacks Equity Research

Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?

by Zacks Equity Research

Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.

Zacks Equity Research

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

by Zacks Equity Research

Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.

Zacks Equity Research

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Zacks Equity Research

Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Zacks Equity Research

Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.

Zacks Equity Research

Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%

by Zacks Equity Research

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Zacks Equity Research

Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates

by Zacks Equity Research

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Zacks Equity Research

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View

by Zacks Equity Research

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

by Zacks Equity Research

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

Zacks Equity Research

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

by Zacks Equity Research

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.

Zacks Equity Research

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

by Zacks Equity Research

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.